Azitra Postpones Special Meeting to Engage Shareholders Effectively

Azitra, Inc., a leading clinical-stage biopharmaceutical company, has recently announced an adjournment of its Special Meeting which was held on February 6, 2026. This decision stems from a failure to achieve the needed quorum, specifically the presence of shares representing 33 1/3% of its outstanding common stock. As a result, the company will reconvene the meeting on March 6, 2026, at 11:00 AM Eastern Time, with the objective of maximizing shareholder participation.

The lack of sufficient votes at the original Special Meeting, which drew only about 13% of the eligible shares, prompted the postponement. During the planned reconvened meeting, shareholders are invited to participate virtually, allowing for listening, voting, and even submitting queries through a web portal. This shift to a virtual format aims to simplify the process and bolster engagement, enabling stockholders to take part in discussions and decisions that directly affect the company’s future.

Proposals for Consideration

The agenda for the reconvened Special Meeting will mirror the initial session’s proposals. The first proposal involves the approval for the issuance of more than 19.99% of the company’s outstanding shares. This issuance is contingent upon compliance with the NYSE American Company Guide and is part of a broader agreement with Alumni Capital LP for a Securities Purchase Agreement originally dated November 24, 2025.

Call to Action for Shareholders

In a bid to rally its stockholders, Azitra encourages those who have yet to cast their votes—especially those uncertain if their votes have been counted—to reach out to their brokers or banks promptly. The company's leadership emphasizes the importance of these decisions and requests that voting be completed by March 6, 2026, at 10:59 AM Eastern Time.

Shareholders who have already submitted a proxy vote but do not wish to alter their decisions need not take further steps. On the flip side, those wishing to change their votes can do so using various methods before the deadline, including mailing a proxy card, voting online, or via phone, ensuring participation in this decisive process.

About Azitra's Innovative Approach

Azitra, Inc. stands out in the biopharmaceutical landscape due to its focus on developing groundbreaking therapies targeted at precision dermatology. The company’s lead initiative, ATR-12, utilizes a specially engineered strain of S. epidermidis designed to address Netherton syndrome, a rare skin condition lacking effective treatment options. Furthermore, Azitra also works on ATR-04, aimed at managing rashes related to EGFR inhibitors, with over 150,000 patients affected in the U.S. Its innovative approach combines advanced biotechnologies and artificial intelligence, showcasing a commitment to leading the field of dermatology.

Azitra's recent activities underscore its dedication to transparent communication with shareholders while actively pursuing its ambitious therapeutic programs. The forthcoming reconvened Special Meeting provides an essential platform for shareholders to influence critical decisions, thereby directly impacting the company's strategic roadmap. For more details, stakeholders can visit Azitra's official website or the SEC portal for filings.

Conclusion

As Azitra prepares for its reconvened Special Meeting, it highlights the significance of shareholder engagement in its corporate governance. This chance to participate in critical decision-making processes not only empowers shareholders but also strengthens the company’s trajectory in the biopharmaceutical industry. By ensuring adequate attendance and fostering dialogue during the next gathering, Azitra aims to pave the way for continued innovation and success in the treatment of complex dermatological conditions.